

Executive Board 10th Session 12-13 May 2009 WHO Geneva, Switzerland

Resolution n°12

Finalisation of UNITAID Strategy Document

The Board of UNITAID asks the Secretariat to finalise the draft strategy, including provisions for Transition of Funding and Monitoring and Evaluation (M&E), to be submitted for review to the Policy and Strategy Committee (PSC) before mid-September 2009, for final validation in December 2009 by the Board.

As part of this endeavour, the Board requests that the UNITAID Secretariat undertake the following tasks:

- 1. Produce an outline of the overarching UNITAID Strategy for review by the Board by the end of the first week of June 2009;
- 2. Convene a Working Group made up of Experts, representatives of the Proposal Review Committee (PRC)/Interim Expert Advisory Group (IEAG), and representatives from the Policy and Strategy Committee (PSC). This Working Group will:
 - a. propose refined market impact criteria and other additional criteria related to UNITAID's mandate regarding medicines, diagnostics and related products for HIV/AIDS, TB and malaria; and
 - b. produce criteria for the identification of co-morbidities which represent potential areas to consider for UNITAID support.

The Transition Strategy should:

- be niche-specific:
- identify transition requirements for UNITAID funded Projects;
- include mechanisms for the monitoring of a Partner's progress towards transition;

The M&E Strategy should build on M&E processes currently in place to monitor UNITAID funded projects. The M&E Strategy should include:

- mechanisms for data collection and designation of responsibilities:
- assessment of market impact and public health benefits;
- measurement of Partner performance;
- measurement of Secretariat and Board performance; and
- monitoring of financial management.

The Secretariat will consult the Board and propose draft Terms of Reference for the M&E Strategy by first week of June 2009. The Terms of Reference will be finalized by the end of June. The first draft of the M&E Strategy will be sent for PSC review by mid September 2009.

Philippe Douste-Blazv